Lavina Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 20-12-2024
- Paid Up Capital ₹ 2.50 M
as on 20-12-2024
- Company Age 20 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.65 Cr
as on 20-12-2024
- Revenue 29.45%
(FY 2022)
- Profit -1.44%
(FY 2022)
- Ebitda 103.30%
(FY 2022)
- Net Worth 12.51%
(FY 2022)
- Total Assets -9.94%
(FY 2022)
About Lavina Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹5.65 Cr.
Jagdish Shawant and Mala Shawant serve as directors at the Company.
- CIN/LLPIN
U24230MH2004PTC149804
- Company No.
149804
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Dec 2004
- Date of AGM
30 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationThane, Maharashtra
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Lavina Pharmaceuticals Private Limited offer?
Lavina Pharmaceuticals Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Malaria Medicine, Antibiotic Tablets, Capsule & Syrup.
Who are the key members and board of directors at Lavina Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jagdish Shawant  | Director | 03-Dec-2004 | Current |
| Mala Shawant | Director | 03-Dec-2004 | Current |
Financial Performance of Lavina Pharmaceuticals.
Lavina Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 29.45% increase. The company also saw a slight decrease in profitability, with a 1.44% decrease in profit. The company's net worth Soared by an impressive increase of 12.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lavina Pharmaceuticals?
In 2022, Lavina Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 31 Oct 2024 | ₹4.00 M | Open |
Hdfc Bank Limited Creation Date: 16 Apr 2024 | ₹4.50 Cr | Open |
Karnataka Bank Ltd. Creation Date: 26 May 2023 | ₹7.50 M | Open |
How Many Employees Work at Lavina Pharmaceuticals?
Unlock and access historical data on people associated with Lavina Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lavina Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lavina Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
